Artifical Intelligence (AI) offers an opportunity to automate parts of jobs Conor McKechnie, VP of Marketing and Strategy, Cytiva, observed, “One major trend we expect to see is an increased focus on precision medicine. Precision medicine involves using genomic data to tailor treatments to an individual's specific genetic makeup, rather than using a one-size-fits-all approach. This approach has the potential to significantly improve patient outcomes and reduce healthcare costs by targeting therapies to those who will most likely benefit from them. We expect to see more personalized cancer therapies and gene therapies that are tailored to specific genetic mutations, as well as an increased use of genomics in drug development.”

Another area of focus for the industry will be the development of new therapies for rare diseases. These diseases often have a small patient population and are therefore less attractive to pharmaceutical companies, which means that patients with rare diseases often have limited treatment options. However, advances in genomics and gene therapy have made it easier to identify and target the genetic causes of rare diseases, and we expect to see more therapies developed specifically for these conditions in the coming year.

“We also expect to see continued growth in the field of regenerative medicine, which involves using stem cells and other techniques to regenerate damaged tissue or organs. This field has already seen significant progress in recent years, with clinical trials underway for therapies that use stem cells to treat conditions such as heart disease, diabetes, and spinal cord injury. We expect to see more clinical trials and potentially even approved therapies in this area in the coming year.”

Chat GPT3 predicts the year in biotech says Cytiva